Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Magnetic imaging agent
Reexamination Certificate
2005-07-12
2005-07-12
Jones, Dameron L. (Department: 1616)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Magnetic imaging agent
C424S001110, C424S001650, C424S009100, C540S465000, C534S010000, C534S014000
Reexamination Certificate
active
06916460
ABSTRACT:
This invention relates to macrocyclic chelants comprised of one or two heteroatom-containing bridges, compositions containing them and their use in medicine, particularly in diagnostic imaging and radiotherapy. This invention relates especially to the use of metal chelates of the macrocyclic chelants as metallopharmaceuticals in Magnetic Resonance Imaging (MRI) and radiopharmaceuticals. This invention also relates to macrocyclic chelants as bifunctional chelating agents (BFC's) for the labeling of biologically active targeting molecules such as proteins, peptides, peptidomimetics, and non-peptide receptor ligands, with metal ions and radioisotopes.
REFERENCES:
patent: 4427646 (1984-01-01), Olexa et al.
patent: 4578079 (1986-03-01), Ruoslahti et al.
patent: 4792525 (1988-12-01), Ruoslahti et al.
patent: 5086069 (1992-02-01), Klein et al.
patent: 5087440 (1992-02-01), Cacheris et al.
patent: 5155215 (1992-10-01), Ranney
patent: 5217705 (1993-06-01), Reno et al.
patent: 5270030 (1993-12-01), Vogel et al.
patent: 5277892 (1994-01-01), Rhodes
patent: 5279812 (1994-01-01), Krstenansky et al.
patent: 5536814 (1996-07-01), Ruoslahti et al.
patent: 5730787 (1998-03-01), Kasai
patent: 5766591 (1998-06-01), Brooks et al.
patent: 5767071 (1998-06-01), Palladino et al.
patent: 5770565 (1998-06-01), Cheng et al.
patent: 5780426 (1998-07-01), Palladino et al.
patent: 5792444 (1998-08-01), Fischman et al.
patent: 5879657 (1999-03-01), DeGrado et al.
patent: 5880281 (1999-03-01), Argese et al.
patent: 6685914 (2004-02-01), Liu
patent: 0 398 143 (1990-11-01), None
patent: 0 410 537 (1991-01-01), None
patent: 0 410 541 (1991-01-01), None
patent: 0 422 937 (1991-04-01), None
patent: 0 422 938 (1991-04-01), None
patent: 0 425 212 (1991-05-01), None
patent: 0 478 328 (1992-04-01), None
patent: 226849 (1925-01-01), None
patent: 2 225 579 (1990-06-01), None
patent: WO 88/07048 (1988-09-01), None
patent: WO 89/05150 (1989-06-01), None
patent: WO 89/10135 (1989-11-01), None
patent: WO 90/00178 (1990-01-01), None
patent: WO 90/03391 (1990-04-01), None
patent: WO 90/15818 (1990-12-01), None
patent: WO 91/01331 (1991-02-01), None
patent: WO 91/15515 (1991-10-01), None
patent: WO 92/13572 (1992-08-01), None
patent: WO 93/12819 (1993-07-01), None
patent: WO 93/17719 (1993-09-01), None
patent: WO 93/23085 (1993-11-01), None
patent: WO 94/00489 (1994-01-01), None
patent: WO 94/03464 (1994-02-01), None
patent: WO 94/05269 (1994-03-01), None
patent: WO 94/26275 (1994-11-01), None
patent: WO 95/14726 (1995-06-01), None
patent: WO 95/28968 (1995-11-01), None
patent: WO 98/15295 (1998-04-01), None
Arap, W., et al., “Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model,”Science, Jan. 16, 1998, 279, 377-380.
Berning, D.E., et al., “Chemical and biomedical motifs of the reactions of hydroxymethylphosphines with amines, amino acids, and model peptides,”J. Am. Chem. Soc., 1999, 121, 1658-1664.
Bousquet, J.-C., et al., “Gd-DOTA: characterization of a new paramagnetic complex,”Radiology, Mar. 1988, 166(3), 693-698.
Burgess, K., et al., Synthesis and solution conformation of cyclo[RGDRGD]: a cyclic peptide with selectivity for the αVβ3 receptor,J. Med. Chem., 1996, 39, 4520-4526.
Burke, T.R., Jr., “Protein-tyrosine kinase inhibitors,”Drugs of the Future, 1992, 17(2), 119-131.
Chang, C.-J., et al., “Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents,”J. of Nat. Prod., Nov. 1992, 55(11), 1529-1560.
Cheung, S.T., et al., “N-methylamino acids in peptide synthesis. V. The synthesis of N-tert-butyloxycarbonyl,N-methylamino acids by N-methylation,” Can.J. Chem., 1977, 55, 906-910.
Corbett, J.W., et al., “Solid-phase synthesis of a selective α,β3integrin antagonist library,”Biorg.&Med. Chem. Letts., 1997, 7(11), 1371-1376.
Cosic, I., et al., “In vitro inhibition of the actions of basic FGF by a novel 16 amino acid peptide,” Molecularand Cell. Biochem., 1994, 130, 1-9.
DeGrado, W.F., et al., “Polymer-bound oxime esters as supports for solid-phase peptide synthesis. Preparation of protected peptide fragments,”J. Org. Chem., 1980, 45, 1295-1300.
Dougher, A.M., et al., “Identification of a heparin binding peptide on the extracellular domain of the KDR VEGF receptor,”Growth Factors, 1997, 14, 257-268.
Fischman, A.J., et al., “Infection imaging with technetium-99m-labeled chemotactic peptide analogs,”Semin. Nuc. Med., Apr. 1994, 24(2), 154-168.
Freidinger, R.M., et al., “Synthesis of 9-fluorenylmethyloxycarbonyl-protected N-alkyl amino acids by reduction of oxazolidinones,”J. Org. Chem., 1983, 48, 77-81.
Fry, D.W., “Protein tyrosine kinases as therapeutic targets in cancer chemotherapy and recent advances in the development of new inhibitors,”Exp. Opin. Invest. Drugs, 1994, 3(6), 577-595.
Gho, Y.S., et al., “Development of antiangiogenin peptide using a phage-displayed peptide library,”Cancer Research, Sep. 1, 1997, 57, 3733-3740.
Hartman, G.D., et al., “Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors,”J. Med. Chem., 1992, 35, 4640-4642.
Haubner, R., et al., “Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the ανβ3integrin for a new cancer therapy,”Angew. Chem. Int. Ed. Engl., 1997, 36, 1374-1389.
Jardines, L., et al., “neu(c-erbB-2/HER2 and the epidermal growth factor receptor (EGFR) in breast cancer,”Pathobiology, 1993, 61, 268-282.
Kolinski, R.A., et al., “Ring inversion in plycyclic tetraamines,”Tetrahedron Letts., 1981, 22(23), 2217-2220.
Maier, L., et al., “Organische phosphorverbindungen 72 Herstellung und eigenschaften von bis(N-hydroxycarbonylmethylamino-methyl)phosphinsäure, (HO2CCH2NHCH2)2P(O)OH, und derivaten,”Phospharus and Sulfur, 1980, 8, 67-72 (English abstract).
Margerstadt, M., et al., “Gd(DOTA): An alternative to Gd(DTPA) as a T1,2relaxation agent for NMR imaging or spectroscopy,”Magn. Reson. Med., 1986, 3, 808-812.
Märkl, V.G., et al., “1,5-diaza-3.7-diphospha-cyclooctane,”Tetrahedron Letts., 1980, 21, 1409-1412.
Merrifield, R.B., “Solid phase peptide synthesis, I. The synthesis of a tetrapeptide,”J. Am. Chem. Soc., 1963, 85, 2149-2154.
Nanda, K.K., et al., “Magneto-structure correlations in macrocyclic dinicke(II) complexes: tuning of spin exchange by varying stereochemistry and auxiliary ligands,”Inorg. Chem., 1994, 33, 1188-1193.
Ortega, N., et al., “Systemic activation of the vascular endothelial growth factor receptor KDR/flk-1 selectively triggers endothelial cells with an angiogenic phenotype,”Amer. J. of Pathol., Nov. 1997, 151(5), 1215-1224.
Ösapay, G., et al., “synthesis of tyrocidine A: use of oxime resin for peptide chain assembly and cyclization,”Tetrahedron Letts., 1990, 31(43), 6121-6124.
Pierschbacher, M.D., et al., “Influence of stereochemistry of the sequence Arg-Gly-Asp-Xaa on binding specificity in cell adhesion,”J. of Biol. Chem., Dec. 25, 1987, 262(36), 17294-17298.
Remington's Pharmaceutical Sciences, 17thEd.,Mack Publishing Co., Easton, PA, 1985, p. 1418.
Rewcastle, G.W., et al., “Tyrosine kinase inhibitors. 5. Synthesis and structure—activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5′-triphosphate binding site inhibitors of the tyrosine kinase domain of epidermal growth factor receptor,”J. Med. Chem., 1995, 38, 3482-3487.
Roberts, D.C., et al., “Unusual amino acids in peptide synthesis,”The Peptides Analysis, Synthesis, Biology, Gross, E., et al. (Eds.), 1983, vol. 5, Chap. 6, 341-449.
Runge, V.M., et al., “MR imaging of rat brain glioma: Gd-DTPA versus Gd-DOTA,”Radiology, 1988, 166, 835-838.
Senger, D.R., et al., “
Bristol-Myers Squibb Pharma Company
Jones Dameron L.
Woodcock & Washburn LLP
LandOfFree
Macrocyclic chelants for metallopharmaceuticals does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Macrocyclic chelants for metallopharmaceuticals, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Macrocyclic chelants for metallopharmaceuticals will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3387944